iPolitics By Janet E Silver. Published on May 3, 2021 11:07am West Block on Parliament Hill (Jolson Lim/iPolitics)
B.C.-based cannabis company Tilray is seeking discussions with Health Canada about the rules governing cannabis beverages, as well as equivalencies with other cannabis products, which became legal in Canada in 2019.
On Monday, Tilray announced the completion of its deal with Aphria to become “a leading cannabis-focused consumer-packaged-goods company.” According to the news release on the company website, it wants to “have a complete portfolio of cannabis 2.0 products to strengthen its leadership position.”
Meanwhile, the Association Québecoise de l’industrie du cannabis is also seeking discussions with the government about topics that include medical-grow licences, additional oversight programs, development of a marketing and branding regime, and the application of excise tax on medical cannabis.
2020 has seen several important developments in product
liability law.
These developments signal that a variety of challenges are on
the horizon for plaintiffs in 2021 in three specific areas: product
liability class actions alleging adverse health effects; claims
relating to the sale of prescription medications; and mass
tort claims.
No workable methodology : an effective defence to
certification
In 2013, the Supreme Court of Canada affirmed in
Pro-Sys
Consultants Ltd. v. Microsoft Corporation
1 that, at
certification, plaintiffs must demonstrate a workable
methodology for determining general causation on a class-wide
basis. Since then, this issue-which has often been decided in the
plaintiffs favour-has arisen frequently in proposed product